IDO1 and neoplasm: Our experimental data unequivocally demonstrated that the most potent bifunctional inhibitor, NK3, directly bonds to IDO1 and STAT3, exhibiting potent in vivo antitumor efficacy in both CT26 tumor-bearing mice and athymic nude mice.